Foamix News. Press Releases.

Press Releases

03/03/2010	Foamix Ltd. and Therapeutics Inc. Enter into Joint Venture to Develop New Prescription Foams for Inflammatory Skin Diseases
04/01/2010	US Grant for Foamix's Saccharide Foam Patent Adds Depth to Foamix's Broad Intellectual Portfolio and Protects Topical "Sweet Foam" Products for Wound & Burn Therapy
04/01/2010	Foamix is a Finalist for the Red Herring 100 Global Award for Most Promising Technology Ventures
04/11/2009	Foamix Expands International Patent Protection for its Emollient Foam Platform
03/11/2009	Foamix Extends Collaboration with Galderma
02/02/2009	Foamix Ltd. and VIB Sign Co-Development Agreement for Innovative Topical Therapy for Psoriasis
28/01/2009	Promius Pharma, LLC Launches Scytera™ (Coal Tar) Foam 2% for Treatment of Psoriasis
08/12/2008	Foamix is Finalist for International 2008 SCRIP Award
03/06/2008	Ferndale and Foamix Execute License Agreement for Development of Non-Steroidal Foam for Atopic Dermatitis
13/05/2008	Omnibus Survey: 72% of Women Are Dissatisfied with Their Current Treatment of Vaginal Infection
29/04/2008	Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
26/03/2008	Foamix is a Finalist for the Red Herring 100 Europe 2008 Award
13/11/2007	Foamix Announces New Foam Patent Approvals
05/11/2007	Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
29/10/2007	Foamix Acquires Rights to Dual Chamber Aerosol Foam Technology
09/07/2007	Foamix Presents Innovative Intra-Vaginal Foam Delivery for Gynecology
24/01/2007	Foamix Signs R&D Collaboration and License Agreement with Dr. Reddy’s for the Development and Commercialization of Psoriasis Foam
20/01/2007	Warner Chilcott and Foamix Collaborate on Gynecologic Foam Product
10/01/2007	Foamix and Intendis Sign License Agreement for the Development of a Dermatological Foam
03/01/2007	Warner Chilcott and Foamix Collaborate on Foam Product for the Treatment of Acne
24/07/2006	Foamix Announces New Waterless Foam Designed for Enhanced Skin Delivery - Useful for Steroids and Water Sensitive Drugs
20/07/2006	Foamix’s Betamethasone Foam Demonstrates High Efficacy in Psoriasis Treatment and 85% Better Usability than Cream in Phase I/II Study
17/07/2006	Foamix Names David Schuz as Senior Vice President, Intellectual Property.
29/03/2006	Foamix CEO to Present “The Changing Face of Dermatology” at the Bio Business Forum at Bio International 2006 in Chicago, April 10, 2006
07/02/2006	Foamix Receives Patents for OilGel™ In the U.S. and in Australia
28/11/2005	Foamix Granted Third U.S. Patent for OilGel™, In Development for Dermatological and Ophthalmic Applications
03/11/2005	Foamix Executive Director Dr. Stanley Hirsch to Present “Foamix - Innovative Delivery in Dermatology” at Bio-Europe 2005, November 8th at 8:30 a.m.
12/09/2005	Foamix Commences Phase II Study of TerbiFoam™ 2% Foam for the Treatment of Athlete’s Foot. Company Concurrently Conducts Phase II Study of Betamethasone 0.12% Emollient Foam for the Treatment of Psoriasis
12/09/2005	Foamix to Showcase Emulsion-Based Cosmetic Foams at The Health and Beauty America (HBA) Conference in New York
18/07/2005	Foamix’s PerFoam™ for the Treatment of Lice Demonstrates Safety and 96% Efficacy in Phase II/III Study
08/06/2005	Foamix Selected to Present at the Bio Business Forum at Bio International 2005 in Philadelphia in June
06/02/2005	Foamix "Breaks the Ribbon" on New Facility
04/02/2005	Foamix Unveils Unique Mupirocin Foam
02/06/2004	Foamix Unveils Innovative Vaginal Foam
15/09/2003	Phase II Psoriasis Study Approved
10/06/2003	Foamix Unveils Revolutionary Dermatological Foams